Dx dialogues: considerations when deciding whether to initiate pharmacologic interventions for patients with AD
Anton Porsteinsson, MD, explains his thought process when deciding whether to initiate a pharmacologic intervention in a patient living with AAD.
Up Next
Dx dialogues: novel approaches in development for the treatment of AD
Dx dialogues: how AI can be integrated in the management of AD
Dx dialogues: overlapping symptomatology of Alzheimer's and other neurodegenerative disorders
Dx dialogues: why early intervention is critical in managing tardive dyskinesia
Dx dialogues: disease-modifying therapies for Alzheimer's and the hope for a cure
Dx dialogues: pharmacologic advances for the treatment and management of schizophrenia
Dx dialogues: blood-based biomarkers and other diagnostic tools for Alzheimer's and related dementias
Dx dialogues: the challenges of treating tardive dyskinesia the "old-fashioned way"
Dx dialogues: VMAT2 inhibitors and future treatments for tardive dyskinesia
Dx dialogues: identifying patients who might benefit from an LAI for schizophrenia
